Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LYRA Stock Forecast 2026-2027
$0.50
Current Price
$878,566
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to LYRA Price Targets
+3,132.3%
To High Target of $16.00
+3,132.3%
To Median Target of $16.00
+3,132.3%
To Low Target of $16.00
LYRA Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-89.2%
1 Year Change
-83.8%
Year-to-Date Change
-98.7%
From 52W High of $37.50
+2.0%
From 52W Low of $0.49
📊 TOP ANALYST CALLS
Did LYRA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Lyra Therapeutics is one of their latest high-conviction picks.
Latest LYRA Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, LYRA has a neutral consensus with a median price target of $16.00 (ranging from $16.00 to $16.00). The overall analyst rating is N/A (N/A/10). Currently trading at $0.50, the median forecast implies a 3,132.3% upside. This outlook is supported by 0 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matthew Caufield at HC Wainwright & Co., projecting a 3,132.3% upside. Conversely, the most conservative target is provided by Matthew Caufield at HC Wainwright & Co., suggesting a 3,132.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LYRA Analyst Ratings
0
Buy
1
Hold
0
Sell
LYRA Price Target Range
Low
$16.00
Average
$16.00
High
$16.00
Current: $0.50
Latest LYRA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LYRA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 14, 2025 | HC Wainwright & Co. | Matthew Caufield | Neutral | Reiterates | $16.00 |
| Jun 10, 2025 | HC Wainwright & Co. | Matthew Caufield | Neutral | Maintains | $16.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Matthew Caufield | Neutral | Reiterates | $2.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Matthew Caufield | Neutral | Reiterates | $2.00 |
| Aug 15, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| Jun 20, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| May 7, 2024 | Jefferies | Dennis Ding | Hold | Downgrade | $0.50 |
| May 7, 2024 | HC Wainwright & Co. | Matthew Caufield | Neutral | Downgrade | $2.00 |
| May 6, 2024 | BTIG | Justin Zelin | Neutral | Downgrade | $N/A |
| May 1, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Mar 25, 2024 | B of A Securities | Jason Gerberry | Buy | Maintains | $11.00 |
| Mar 22, 2024 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Oct 6, 2023 | BTIG | Justin Zelin | Buy | Assumes | $15.00 |
| Oct 2, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Reiterates | $12.00 |
| Sep 12, 2023 | B of A Securities | Jason Gerberry | Buy | Maintains | $15.00 |
| Aug 31, 2023 | HC Wainwright & Co. | Matthew Caufield | Buy | Initiates | $12.00 |
| Feb 7, 2023 | BTIG | Robert Hazlett | Buy | Maintains | $20.00 |
| May 24, 2022 | Cantor Fitzgerald | Louise Chen | Overweight | Initiates | $15.00 |
| May 26, 2020 | B of A Securities | Buy | Initiates | $N/A | |
| May 26, 2020 | Jefferies | Buy | Initiates | $N/A |
Lyra Therapeutics Inc. (LYRA) Competitors
The following stocks are similar to Lyra Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lyra Therapeutics Inc. (LYRA) Financial Data
Lyra Therapeutics Inc. has a market capitalization of $878,566 with a P/E ratio of 0.0x. The company generates $600,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -87.2% quarter-over-quarter, while maintaining an operating margin of -25,032.0% and return on equity of -404.5%.
Valuation Metrics
Market Cap
$878,566
Enterprise Value
$11.67M
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
3.9x
Growth & Margins
Revenue Growth (YoY)
-87.2%
Gross Margin
N/A
Operating Margin
-25,032.0%
Net Margin
0.0%
EPS Growth
-87.2%
Financial Health
Cash/Price Ratio
+2,510.3%
Current Ratio
2.4x
Debt/Equity
-7.3x
ROE
-404.5%
ROA
-33.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lyra Therapeutics Inc. (LYRA) Business Model
About Lyra Therapeutics Inc.
What They Do
Develops therapies for ear, nose, and throat diseases.
Business Model
Lyra Therapeutics operates by creating innovative polymer-based drug delivery systems, specifically its XTreo platform, which allows for sustained medication delivery directly to sites affected by chronic rhinosinusitis and other ENT conditions. This targeted approach not only enhances treatment effectiveness but also mitigates systemic side effects, contributing to improved patient outcomes and driving revenue through specialized pharmaceutical sales.
Additional Information
The company is positioned to significantly impact the healthcare market by offering novel localized therapies that address the underlying causes of ENT diseases, setting a new standard in the specialty pharmaceuticals industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
30
CEO
Dr. Maria Palasis Ph.D.
Country
United States
IPO Year
2020
Website
lyratherapeutics.comLyra Therapeutics Inc. (LYRA) Latest News & Analysis
Latest News
Quick Summary
Lyra Therapeutics, Inc. plans to file a Form 25 for delisting from Nasdaq on April 20, 2026, following suspension of its stock trading on March 17, 2026. It will now be quoted on the Pink Limited Market.
Why It Matters
Lyra Therapeutics' delisting from Nasdaq signals reduced liquidity and transparency, potentially increasing volatility and risk for remaining investors in its common stock.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Lyra Therapeutics Provides Corporate Update
3 months ago
Quick Summary
Lyra Therapeutics, Inc. (Nasdaq: LYRA) announced the suspension of development for LYR-210, its lead candidate for chronic rhinosinusitis, effective January 12, 2026.
Why It Matters
The suspension of LYR-210 development raises concerns about Lyra Therapeutics' growth potential and could negatively impact stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
5 months ago
Quick Summary
The company is initiating a confirmatory Phase 3 clinical trial for LYR-210 to treat chronic rhinosinusitis without nasal polyps, aiming for NDA submission.
Why It Matters
The new Phase 3 trial for LYR-210 signals progress towards FDA approval, potentially boosting the company's market position and driving stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lyra Therapeutics (LYRA) reported a quarterly loss of $3.38 per share, better than the estimated loss of $5.98 and an improvement from a $9 loss per share a year earlier.
Why It Matters
Lyra Therapeutics' smaller-than-expected loss suggests improving financial health, potentially boosting investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Lyra Therapeutics (Nasdaq: LYRA) announced its clinical plan for LYR-210, following positive ENLIGHTEN 2 trial results. An oral presentation is scheduled for the AAO-HNS 2025 Annual Meeting.
Why It Matters
The announcement of positive Phase 3 trial results and a clear clinical plan for LYR-210 signals potential for regulatory approval and market entry, likely boosting investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
8 months ago
Quick Summary
Positive Phase 3 ENLIGHTEN 2 results for LYR-210 advance manufacturing, regulatory strategies, and clinical analysis aimed at treating chronic rhinosinusitis (CRS).
Why It Matters
Positive Phase 3 results for LYR-210 indicate strong potential for market approval, boosting investor confidence in the company's growth and future revenue from CRS treatment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LYRA Stock
What is Lyra Therapeutics Inc.'s (LYRA) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Lyra Therapeutics Inc. (LYRA) has a median price target of $16.00. The highest price target is $16.00 and the lowest is $16.00.
Is LYRA stock a good investment in 2026?
According to current analyst ratings, LYRA has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LYRA stock?
Wall Street analysts predict LYRA stock could reach $16.00 in the next 12 months. This represents a 3,132.3% increase from the current price of $0.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lyra Therapeutics Inc.'s business model?
Lyra Therapeutics operates by creating innovative polymer-based drug delivery systems, specifically its XTreo platform, which allows for sustained medication delivery directly to sites affected by chronic rhinosinusitis and other ENT conditions. This targeted approach not only enhances treatment effectiveness but also mitigates systemic side effects, contributing to improved patient outcomes and driving revenue through specialized pharmaceutical sales.
What is the highest forecasted price for LYRA Lyra Therapeutics Inc.?
The highest price target for LYRA is $16.00 from Matthew Caufield at HC Wainwright & Co., which represents a 3,132.3% increase from the current price of $0.50.
What is the lowest forecasted price for LYRA Lyra Therapeutics Inc.?
The lowest price target for LYRA is $16.00 from Matthew Caufield at HC Wainwright & Co., which represents a 3,132.3% increase from the current price of $0.50.
What is the overall LYRA consensus from analysts for Lyra Therapeutics Inc.?
The overall analyst consensus for LYRA is neutral. Out of 7 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are LYRA stock price projections?
Stock price projections, including those for Lyra Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 6:07 PM UTC